A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Other, Drug
Study Type: Observational
SUMMARY
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Signed Informed Consent obtained before any trial-related procedures.
• Previous participation in the clinical trial ConfIdeS.
Locations
United States
Alabama
University of Alabama at Birmingham (UAB) Hospital
RECRUITING
Birmingham
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
Illinois
Northwestern University, Dept. General Surgery, Div. Transplantation
RECRUITING
Chicago
University of Chicago, Department of Surgery, Clinical Research Center
RECRUITING
Chicago
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Maryland
John Hopkins Hospital
RECRUITING
Baltimore
Missouri
Washington University School of Medicine
RECRUITING
St Louis
New Jersey
Cooperman Barnabas Medical Center
RECRUITING
Livingston
New York
Columbia University
RECRUITING
New York
New York University (NYU) Langone Transplant Institute, NYU Langone Health
RECRUITING
New York
Texas
Houston Methodist Hospital
RECRUITING
Houston
Methodist Hospital Specialty and Transplant
RECRUITING
San Antonio
Washington
University of Washington Medical Center
RECRUITING
Seattle
Wisconsin
Medical College of Wisconsin
RECRUITING
Milwaukee
Contact Information
Primary
Central Contact
clinicalstudyinfo@hansabiopharma.com
+46 46 16 56 70
Time Frame
Start Date: 2023-04-21
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 64
Treatments
Imlifidase administered in the ConfIdeS study
Best available treatment administered in the ConfIdeS study
Related Therapeutic Areas
Sponsors
Leads: Hansa Biopharma AB